Page 9 - Sanofi Canada News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Fifth indication for DUPIXENT ® in Canada following approvals for moderate-to-severe atopic dermatitis in adults and adolescents, severe chronic rhinosinusitis with nasal polyposis, and severe asthma in adults and adolescents. For those living with atopic dermatitis, itch has the highest impact on a patient s quality of life. 1 Results from a survey conducted among Canadian children with atopic dermatitis found that 70 per cent experienced loss of sleep and 30 per cent experienced anxiety due to their condition. 2 MISSISSAUGA, ON, Feb. 23, 2021 /CNW/ - Sanofi Canada announced today that Health Canada has approved DUPIXENT ® (dupilumab injection) for the treatment of moderate-to-severe atopic dermatitis (AD) in children aged six to 11 years whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Melinda gooderhamMarissa pooleSkin centre for dermatologyEczema society of canadaHealth canadaMedical directorEczema societyCountry leadSanofi canadaGeneral managerSanofi genzymeமெலிண்டா குட்ஹாம்மரிசா பூல்தோல் மையம் க்கு தோல் நோய்அரிக்கும் தோலழற்சி சமூகம் ஆஃப் கனடாஆரோக்கியம் கனடா